中耳炎试验在ClinicalTrials.gov注册后的发表情况
该横断面观察研究检索ClinicalTrials.gov中主完成日期早于2022年1月1日的已完成中耳炎试验,通过系统检索判定发表状态并用多因素logistic回归分析相关因素。256项已完成试验中仅18.4%(47项)发表,生物制剂试验发表比例最高(81.3%),药物、器械、操作及其他试验发表比例较低。
要点
- 256项已完成中耳炎试验中仅18.4%(47项)发表。
- 生物制剂试验发表比例最高(81.3%),主要为肺炎球菌结合疫苗研究。
- 干预性试验发表比例高于观察性试验(24.2% vs 2.9%)。
核心结论
- 不足五分之一的中耳炎试验被发表,该比例明显低于其他耳鼻咽喉亚专科。
- 肺炎球菌结合疫苗试验发表比例高,但多数其他类别试验发表滞后。
- 作者认为需要在研究 pipeline 各环节加大投入以推动中耳炎治疗创新。
研究设计与样本
- 横断面观察研究,数据来源为ClinicalTrials.gov注册库与同行评议文献数据库。
- 检索ClinicalTrials.gov中主完成日期早于2022年1月1日的已完成中耳炎相关试验。
- 按干预类型、申办方、分期、年龄组和主要研究者所在地对试验分类。
- 通过系统检索ClinicalTrials.gov、PubMed和Google Scholar判定发表状态。
- 采用多因素logistic回归识别与发表相关的因素。
主要发现
- 256项已完成中耳炎试验中仅18.4%(47项)发表。
- 生物制剂试验发表比例最高(81.3%),主要为评估肺炎球菌结合疫苗(PCV)的研究。
- 药物试验发表比例20.5%,操作试验18.8%,器械试验8.9%,其他试验8.0%。
- 干预性试验发表比例高于观察性试验(24.2% vs 2.9%)。
- 多因素分析中,生物制剂干预、干预性研究设计和以儿童为焦点的研究是发表的显著预测因素;与生物制剂相比,药物、器械和操作试验发表的比值比显著更低;仅成人研究和观察性试验也更少发表。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the proportion of completed otitis media (OM) clinical trials registered on ClinicalTrials.gov and identify factors associated with nonpublication. STUDY DESIGN: Cross-sectional observational study. SETTING: ClinicalTrials.gov registry and peer-reviewed literature databases. METHODS: ClinicalTrials.gov was queried for completed OM-related trials with primary completion dates before January 1, 2022. Trials were categorized by intervention type, sponsorship, phase, age group, and principal investigator location. Publication status was determined through systematic searches of ClinicalTrials.gov, PubMed, and Google Scholar. Multivariable logistic regression identified factors associated with publication. RESULTS: Of 256 completed OM trials, only 18.4% (47) were published. Biologic trials-primarily studies evaluating pneumococcal conjugate vaccines (PCVs)-had the highest proportion published (81.3%), followed by drug trials (20.5%), procedure trials (18.8%), device trials (8.9%), and other trials (8.0%). Interventional trials were more frequently published than observational trials (24.2% vs 2.9%). In multivariable analysis, biologic interventions, interventional study design, and child-focused studies were significant predictors of publication. Drug, device, and procedure trials had significantly lower odds of publication compared to biologics. Adult-only studies and observational trials were also less likely to be published. CONCLUSION: Fewer than 1 in 5 OM trials were published-a proportion substantially lower than in other otolaryngology subspecialties. While PCV trials had high publication proportions, most other categories lagged. Greater investment across the research pipeline is needed to drive innovation in OM therapy.
引用
- Oca M, Rajan SM, Qian ZJ, et al. Otitis Media Trial Publication After ClinicalTrials.gov Registration. Otolaryngol Head Neck Surg. 2025. PMID: 40728105. doi:10.1002/ohn.1366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。